Crystalline and non-crystalline forms of SGLT2 inhibitors
AssigneeScinoPharm Taiwan, Ltd.
InventorsJulian Paul Henschke, Meng-Fen Ho, Shu-Ping Chen, Yung-Fa Chen
Life of this patent
Estimating the term…
Abstract
The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.
Claims10
A crystalline complex form of canagliflozin selected from the group consisting of Form CS2, CS3, CS4 and CS5, wherein said crystalline form is substantially free of other crystalline forms.
A composition comprising a pharmaceutically acceptable excipient and a crystalline complex form of canagliflozin having a form selected from the group consisting of Form CS2, Form CS3, Form CS4 and Form CS5.
Dependencies are inferred from the claim text.